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Abstract
Background: Robot-assisted gait training (RAGT) was developed to restore gait function by promoting neuroplasticity
through repetitive locomotor training and has been utilized in gait training. However, contradictory outcomes of RAGT
have been reported for patients with Parkinson’s disease (PD). In addition, the mechanism of the RAGT treatment effect
is still unknown. This study aims to investigate the effects of RAGT on gait velocity in patients with PD and to unveil
the mechanisms of these effects.
Methods: This is a prospective, single-blind, single-center, randomized controlled trial. Eligible participants will be
randomly allocated to: 1) a Walkbot-S™ RAGT group or 2) a treadmill training group. The participants will receive three
45-min sessions of each intervention per week for 4 weeks. Gait speed during RAGT will be targeted to the maximal
speed depending on the participant’s height; the same principle will be applied to the treadmill training group to
match the training intensity. The primary outcome measure is gait speed measured by the 10-Meter Walk Test at a
comfortable pace under single-task conditions. Secondary outcomes include dual-task interference, the Berg Balance
Scale, Timed Up and Go test, the Korean version of the Falls Efficacy Scale-International, New Freezing of Gait Questionnaire,
Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale, and functional connectivity
measured by resting-state functional magnetic resonance imaging. Baseline assessments (T0) will be conducted to acquire
clinical characteristics and outcome measure values before the intervention. Postintervention assessments (T1) will compare
immediate efficacies within 3 days after the intervention. Follow-up assessments (T2) will be conducted 1 month after the
intervention. Considering an alpha of 0.05 and a power of 80%, the total number of participants to be recruited is 44.
Discussion: This study will reveal the effect of RAGT using an exoskeletal robot, not only on gait speed, but also on gait
automaticity, balance function, fall risk, quality of life, and disease severity. In addition, the study will shed new light on the
mechanism of the RAGT effect by evaluating changes in gait automaticity and brain functional networks.
Trial registration: ClinicalTrials.gov, NCT03490578. Registered on 21 March 2018.
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Background
Robot-assisted gait training (RAGT) was developed to
restore gait function by promoting neuroplasticity
through repetitive locomotor training [1]. Exoskeletal
and end-effector robots have been commercialized and
utilized in gait rehabilitation [2]. In the area of brain dis-
eases, most clinical studies have been conducted on
stroke patients. According to a recent systematic review,
machine- and robot-assisted gait training improved
walking independency in subacute stroke patients who
could not walk by themselves [3]. The American Heart
Association/American Stroke Association (AHA/ASA)
guideline for adult stroke rehabilitation recommended
RAGT to improve motor function and mobility with a
class IIb level of evidence A [4]. However, there is still a
lack of studies of RAGT in brain diseases other than
stroke, and clear guidelines are not provided.
Parkinson’s disease (PD) is a neurodegenerative dis-
order presenting with resting tremor, rigidity, bradykine-
sia, postural instability, and gait disturbance. Gait
disturbance is one of the most disabling symptoms of
PD [5]. Reduced step height, short stride, slow gait, and
freezing of gait are common gait problems in patients
with PD. Although pharmacological treatment has been
the mainstay of PD management, most patients experi-
ence functional aggravation despite optimal medication
[6]. Deep brain stimulation, a surgical intervention to
treat PD, has become an acceptable treatment option.
However, because of the risks and complications of the
procedure, it has been limited to some advanced patients
with medically refractory symptoms [7]. So far, no cure
for PD has been developed. Therefore, rehabilitation has
been an essential element in maintaining the maximum
level of mobility and independence in patients with PD.
For gait rehabilitation in PD, treadmill training has been
a common approach. Thus, conventional treadmill train-
ing was selected as a comparator in this study protocol.
A major impairment causing gait disturbance in PD is
the hypokinesia of gait [8]. Gait hypokinesia is associated
with reduced stride length and step height, decreased ca-
dence, and prolonged double limb support. It is one of
the most disturbing symptoms affecting quality of life in
PD [9] and can be quantified as the gait velocity. De-
creased gait automaticity is another important cause of
gait disturbance in PD [10]. Once a skilled movement
has been learned, the movement becomes automatic and
does not require much conscious endeavor or attention.
Gait automaticity refers to the ability to walk without
cognitive effort or attention [11]. In patients with PD,
loss of dopamine in the sensorimotor territories of the
basal ganglia disturbs habitual control [12], so that gait
automaticity is decreased and patients have to rely on at-
tentional resources or make a conscious effort to walk.
Dual-task performance demands greater attentional cost
and cognitive effort, and therefore gait automaticity can
be quantified as the dual-task interference. For these
reasons, this study will focus on the change in gait vel-
ocity and dual-task interference between before and after
the intervention.
There are studies of the effects of RAGT on gait vel-
ocity with better outcomes for RAGT than the control
group [13–16], as well as insignificant outcomes [17–
19]. Some studies on PD have suggested that RAGT
might improve freezing of gait, postural instability, and
gait performance [13–16, 20]; however, several studies
have reported that RAGT is not superior to conven-
tional therapy for improving postural instability and gait
performance [17, 18, 21]. Due to the contradictory re-
sults, a well-designed study is needed to clarify the effect
of RAGT on gait function in PD. Impaired automaticity
leads to gait disturbance and falls in PD, especially in sit-
uations when the patients conduct secondary tasks in
parallel with gait. So far, there are no studies that have
investigated the effect of RAGT on gait automaticity in
PD; therefore, a further study is needed to reveal this
effect.
There appears to be an association between brain net-
works and gait function in PD. Functional connectivity
has been reported to be decreased even in the early
stages of PD [22, 23], and freezing of gait might be a
consequence of alterations in brain functional networks
[24, 25]. RAGT was suggested to improve gait recovery
by promoting brain plasticity [26]. Therefore, there is a
need to study changes in functional connectivity after
RAGT in PD. In this study, resting-state functional mag-
netic resonance imaging (MRI) will be conducted to dis-
cover significant changes in functional connectivity and
compare the functional networks of the brain before and
after the intervention.
The primary objective of this study is the verification
of the hypothesis that RAGT can produce greater im-
provement, compared with conventional treadmill train-
ing, in gait speed at a comfortable pace. Secondarily, this
study aims to determine whether gait automaticity, bal-
ance, mobility, fall risk, and disease severity are im-
proved by RAGT. Thirdly, this trial will shed new light
on the mechanism of the RAGT treatment effect by in-
vestigating dual-task interference and functional con-
nectivity before and after the intervention.
Methods
Trial design
This is a prospective, single-blind (assessors), single-cen-
ter, randomized controlled trial. Eligible participants will
be randomly allocated to: 1) a RAGT group or 2) a
treadmill training group. Figure 1 shows the Consoli-
dated Standards of Reporting Trials (CONSORT) flow
diagram for this study. Baseline assessments (T0) will be
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conducted to acquire clinical characteristics and values
of the primary and secondary outcome measures before
the intervention. Postintervention assessments (T1) to
compare the immediate efficacy between the two groups
will be performed within 3 days after the intervention.
Follow-up assessments (T2) will be conducted 1 month
after the intervention. All procedures have been ap-
proved by the Institutional Review Board of the Seoul
National University Hospital in accordance with good
clinical practices, the Helsinki Declaration, and national
regulations. The clinical trial was also approved by the
Korean Ministry of Food and Drug Safety.
Sample size
The primary outcome measure in this study is gait speed
in postintervention assessments measured by the 10-m
walk test (10MWT) at a comfortable pace under
single-task conditions. Previous studies, in which similar
populations and intervention protocols were employed,
have reported that the minimal detectable change in
comfortable gait speed measured by the 10MWT was
0.18 m/s [27] and the standard deviation was 0.08–0.20
m/s [13, 17]. Based on those findings, we consider 0.18
m/s as a clinically significant improvement in gait speed
and 0.20 m/s as an acceptable standard deviation. Conse-
quently, 20 participants per group will be required to
achieve 80% power with a two-tailed α of 0.05, as deter-
mined by [28]:
N ¼ 2SD
2 Zα þ Zβ
 2
△2
With an expected drop-out rate of 10%, a total of 44
participants should be recruited, 22 for each group, to
establish the relative efficacy of each intervention in im-
proving gait velocity.
Participants
In total, 44 participants will be recruited from the De-
partment of Rehabilitation of the Seoul National Univer-
sity Hospital (Seoul, Republic of Korea). Approved trial
posters including the inclusion, exclusion criteria, and
contact details of researchers will be displayed in appro-
priate clinics.
The inclusion criteria are:
 Clinically diagnosed as idiopathic PD
 Men or women aged ≥ 18 years
 Hoehn-Yahr stage 2.5 or 3
 Mini-Mental State Examination (MMSE) score ≥ 24
The exclusion criteria include:
 Severe dyskinesia or severe on-off phenomenon
 Plan to adjust medication at the time of screening
 Sensory dysfunction in lower extremities
 Vestibular disease or benign paroxysmal positional
vertigo
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) flow diagram
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 Severe medical problems such as cardiovascular
diseases
 Other neurological or orthopedic disorders affecting
lower extremities
Participants will be individually consented to partici-
pate in the entire study. The Principal Investigator and
clinical research coordinator will obtain the written in-
formed consent from all participants.
Randomization and blinding
Randomization and allocation will be performed using
computer-generated block randomization with a block
size of 4 and 6. An independent researcher who is not in
contact with any patient will perform the randomized al-
location. The ratio between the RAGT and treadmill
training groups will be 1:1. Details of the allocated group
will be given in sequentially numbered, opaque, sealed
envelopes to the research assistants in sequential order.
The principal investigator, outcome assessors, and data
analysts will be blinded to the group allocations of the
participants until statistical analysis.
Interventions
Participants in the RAGT group will receive gait training
with the Walkbot-S™ (P&S Mechanics, Seoul, Korea) for
12 sessions (Fig. 2). Training is preceded by fitting and
adapting the equipment to the participant. In the first
training session, RAGT starts at the reference velocity
depending on the participant’s height (Table 1) and
reaches 80% of the maximal velocity at the end. Starting
with the third training session, the initial gait velocity is
increased and the final velocity becomes the maximal
velocity depending on the participant’s height. Starting
with the seventh training session, training velocity
reaches the maximal velocity after 10 min. Table 2 shows
an example of a training protocol for a participant whose
height is 160 cm.
During gait training, the robot provides an auditory
cue at the toe-off phase to improve gait rhythmicity.
Moreover, the robot provides a visual feedback by dis-
playing a warning message on the screen when the
torque exceeds a preset target range, which induces ac-
tive hip flexion. The cue and feedback are designed to
induce active participation in the training. The treatment
time per session is 45 min, including don-and-doff,
warm-up, and cool-down. The actual RAGT time is 30
min. A total of 12 sessions are provided over the course
of 4 weeks.
Participants in the treadmill training group receive gait
training on the treadmill. The same velocity protocol as
in the RAGT group is applied to the treadmill training
group to match the training intensity. A physical therap-
ist provides appropriate visual and auditory instructions
to allow the patient to participate in gait training ac-
tively. The treatment time per session is 45 min, includ-
ing warm-up and cool-down. The actual treadmill
training time is 30 min. A total of 12 sessions are pro-
vided over the course of 4 weeks.
The participants are contacted by phone and mobile
text message 1 day before each session to improve ad-
herence. During the clinical trial, participants are pro-
hibited from changing the regimen of dopaminergic
medication but they are permitted to keep the previous
rehabilitation therapy that was already received. The par-
ticipation can be discontinued due to the occurrence of
serious adverse events or at the participant’s request. Fi-
delity of the intervention will be assessed through docu-
menting the number and duration of sessions and the
minimal and maximal velocity of each session delivered.
Outcome measures
The primary outcome measure is gait speed measured
by the 10MWT at a comfortable pace under single-task
conditions [29]. The 10MWT is a common measure to
Fig. 2 a The Walkbot-S™, an exoskeletal-type gait training robot; b a patient participating in gait training using Walkbot-S™
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evaluate gait velocity and highly reliable for assessing
gait speed in patients with PD [29].
The secondary outcomes include dual-task interference
[30], the Berg Balance Scale (BBS) [31], Timed Up and Go
(TUG) test [32], the Korean version of the Falls Efficacy
Scale-International (KFES-I) [33, 34], the New Freezing of
Gait Questionnaire (NFOG-Q) [35], and the Movement
Disorder Society-sponsored revision of the Unified Parkin-
son’s Disease Rating Scale (MDS-UPDRS) [36].
Dual-task interference, an indicator of gait automaticity,
is defined by the difference between dual- and single-task
performance [37]. To evaluate dual-task performance,
cognitive dual-task walking [38] will be measured while
performing the Wechsler Forward Digit Span [39], and
physical dual-task walking will be measured while carrying
a tray with two cups of water [40, 41]. The BBS measures
balance function during sitting, standing, and changing
positions. It consists of 14 items and the total score ranges
from 0 to 56 [42]. The tool is clinically valid in PD patients
[31]. The TUG test is a reliable measure for mobility in
the elderly. During the test, patients stand up from a chair,
walk for 3m, turn, walk back, and sit down. It is also a
highly reliable tool to assess mobility in PD [32]. KFES-I is
a valid method to assess fear of falling in the elderly [33].
It is a self-reported measure of concerns about falls during
activities of daily living. It consists of 16 items scored on a
four-point scale [34]. NFOG-Q is a freezing of gait (FOG)
questionnaire which assesses FOG severity and gait distur-
bances. It is a reliable tool to measure the FOG and the
functional impact in patients with PD [35]. MDS-UPDRS,
a clinical rating scale for PD, contains four parts [36]. A
total of 50 questions rate disability or impairment on a
scale of 0–4.
The 10MWT, BBS, and TUG test will be assessed by a
physical therapist and the MDS-UPDRS will be adminis-
tered by a licensed clinician. All assessors will be blinded
to group assignment. Figure 3 shows the schedule for
outcome measures evaluated at each visit.
Functional MRI
Functional MRI will be employed to analyze functional
connectivity before and after the intervention. Images
will be obtained by a 3-T scanner (Siemens Magnetom
TrioTim) using the following parameters: 116 volumes
with a matrix size of 128 × 128 mm and a voxel size of
1.88 × 1.88 × 4.20 mm, TR = 3500 ms, TE = 30ms, flip
angle = 90°, and FOV = 240 × 240mm. All participants
will be instructed to remain still but awake with the eyes
closed during the resting-state functional MRI scan.
Data collection, management, and dissemination
Demographic data including age, sex, height, duration of
disease, Hoehn-Yahr stage, MMSE score, and comorbidi-
ties will be obtained. Outcome measures at T0, T1, and
T2 will be acquired as well. All data will be de-identified
using an identification number to provide confidentiality
and will be collected on paper case report forms and
password-protected digital files. Paper case report forms
and digital files will be stored in a locked cabinet in a
locked office and on a password-protected computer in
a locked office, respectively. An independent clinical re-
search assistant will verify the data by review of medical
records once a month to guarantee data quality includ-
ing completeness and accuracy. Any adverse events, any
untoward medical occurrence associated with the inter-
vention of this study, will be recorded and reported to
the Institutional Review Board and Korean Ministry of
Food and Drug Safety (KMFDS). Additional medical
procedures will be provided depending on the event.
Trial management may be audited by the KMFDS which
is independent of investigators at any time.
All authors will have access to the final dataset. Upon
completion, trial results will be reported to the funders
Table 1 Walkbot-S™ reference and maximal velocities depending on height
Height
140 cm 150 cm 160 cm 170 cm 180 cm 190 cm 200 cm
Reference velocity (m/s) 1.0 1.1 1.2 1.3 1.4 1.5 1.6
Maximal velocity (m/s) 1.8 2.0 2.2 2.4 2.6 2.8 3.0
Table 2 Example of a training velocity protocol for a 160-cm
tall participant
No. of minutes
0–5 5–10 10–15 15–20 20–25 25–30 30
Training session no. Velocity, m/s
1 1.2 1.2 1.4 1.4 1.7 1.7 1.7
2 1.2 1.2 1.4 1.4 1.7 1.7 1.7
3 1.4 1.4 1.8 1.8 2.2 2.2 2.2
4 1.4 1.4 1.8 1.8 2.2 2.2 2.2
5 1.7 1.7 2 2 2.2 2.2 2.2
6 1.7 1.7 2 2 2.2 2.2 2.2
7 1.9 1.9 2.2 2.2 2.2 2.2 2.2
8 1.9 1.9 2.2 2.2 2.2 2.2 2.2
9 1.9 1.9 2.2 2.2 2.2 2.2 2.2
10 1.9 1.9 2.2 2.2 2.2 2.2 2.2
11 1.9 1.9 2.2 2.2 2.2 2.2 2.2
12 1.9 1.9 2.2 2.2 2.2 2.2 2.2
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and submitted to peer-reviewed journals to communi-
cate to participants, healthcare professionals, and the
public. Authorship will follow guidelines recommended
by the International Committee of Medical Journal Edi-
tors (ICMJE). Professional writers will not be employed.
Statistical analysis
Data will be analyzed using the Statistical Package for
the Social Sciences (SPSS) version 20. Statistical signifi-
cance will be accepted when a p value is less than 0.05.
The intention-to-treat (ITT) principle will be adopted in
all analyses. All participants randomized to a group will
remain in the group regardless of protocol violations or
dropout. Last observation carried forward (LOCF) will
be used to impute missing values. Per-protocol analyses
will also be conducted. All participants from the ITT
population without serious protocol violations will be in-
cluded in the per-protocol population. Serious violations
include exceptions to eligibility criteria and deviations
from the treatment scheme such as not completing at
least eight of the total of 12 sessions.
For the primary outcome analysis, the change between
T0 and T1 in gait speed at a comfortable pace under
single-task conditions will be analyzed using Student’s t
test. Generalized estimating equation (GEE) models will
be employed to identify differential changes of secondary
outcome measures across multiple time points.
Functional connectivity in the whole brain area will be
analyzed using the primary motor cortex as a seed region.
Pearson’s correlation coefficient will be used to calculate
functional connectivity. Comparisons of functional con-
nectivity will be conducted using two sample t tests for
between-group differences and paired t tests for
within-group effects.
Discussion
Robots have been increasingly used for gait rehabilita-
tion, especially in patients with brain diseases such as
stroke and multiple sclerosis [43, 44]. However, contra-
dictory results have been reported by studies of RAGT
in patients with PD. In addition, there are no clinical
guidelines for RAGT in gait training for PD. Moreover,
even in studies reporting gait improvement by RAGT in
Fig. 3 Study schedule of enrollment, interventions, and assessments. 10MWT 10-m walk test, BBS Berg Balance Scale, KFES-I Korean version of the Falls
Efficacy Scale-International, MDS-UPDRS Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale, NFOG-Q New
Freezing of Gait Questionnaire, RAGT robot-assisted gait training, rs-fMRI resting-state functional magnetic resonance imaging, TUG Timed Up and Go
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PD, the mechanism of the treatment effect remains
elusive.
RAGT in this study will include a visual feedback and
an auditory cue, which are known as effective strategies to
treat locomotor impairments [45]. Feedback or cues were
reported to improve gait performance in patients with PD
[46], and an additional beneficial effect of cues with gait
training has been suggested [47]. External cues appear to
help patients with PD walk better by compensating for the
impaired central drive for walking [48]. Another hypoth-
esis is that external cues enable patients to utilize the in-
tact premotor cortex, rather than the impaired basal
ganglia/supplementary motor area circuit [49]. Therefore,
RAGT including external cues or feedback is expected to
improve gait performance in patients with PD.
This study will reveal the effect of RAGT using an
exoskeletal robot, not only on comfortable gait speed,
but also on dual-task interference, balance function, fall
risk, and disease severity. In addition, the findings of the
study will provide knowledge on the recovery of gait
automaticity and brain functional connectivity following
RAGT. We hope that the information acquired from this
trial will advance our understanding of the mechanism
of the RAGT treatment effect and improve clinical deci-
sion making when physiatrists consider gait training for
patients with PD.
A limitation of this study is that it involves only one
center. This might influence the generalizability of the
results to other centers. Another limitation is that blind-
ing of patients and therapists is not possible due to the
definite different feature of the interventions.
In summary, this trial will compare the effects of
RAGT with those of treadmill training on gait perform-
ance in patients with PD. The results of this study will
provide clear evidence whether RAGT rather than tread-
mill training may be recommended for gait training in
patients with PD.
Trial status
This study was initiated in May 2018, and patient re-
cruitment is ongoing. The trial will be completed in De-
cember 2019.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) Checklist. (DOC 121 kb)
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